Quest Diagnostics Acquires Haystack Oncology

insitro Acquires Haystack Sciences

October 22, 2020

Biotechnology

insitro has acquired Haystack Sciences to integrate Haystack’s DNA-encoded library (DEL) technology and nDexer platform into insitro’s machine-learning-driven drug discovery efforts. The acquisition expands insitro’s small-molecule design and high-throughput chemistry capabilities to accelerate predictive model-driven therapeutics discovery; financial terms were not disclosed.

Quest Diagnostics Acquires Pack Health

January 18, 2022

Healthcare Services

Quest Diagnostics has entered into a definitive agreement to acquire Pack Health in an all-cash transaction. The acquisition brings Pack Health's patient-engagement platform and certified health coaches into Quest's Extended Care services to strengthen value-based care and connect diagnostic insights to action.

Labcorp Acquires Personal Genome Diagnostics (PGDx)

February 21, 2022

Healthcare Services

Labcorp completed its acquisition of Personal Genome Diagnostics (PGDx), a cancer genomics company that develops liquid biopsy and tissue-based NGS products. Labcorp paid $450 million in cash at closing plus up to $125 million in performance-based milestones to expand its oncology genomics and liquid biopsy capabilities and accelerate access to precision diagnostics for clinical care and trials.

Quest Diagnostics Acquires Labtech Diagnostics

December 14, 2021

Healthcare Services

Quest Diagnostics has acquired substantially all assets of Labtech Diagnostics, an independent clinical diagnostic laboratory based in Anderson, South Carolina. The acquisition brings Labtech into Quest’s national laboratory network — Quest’s first full-service laboratory in South Carolina — and expands Quest’s diagnostic capabilities and presence across the Southeast.

Natera Acquires Foresight Diagnostics

December 11, 2025

Healthcare Services

Natera has completed its acquisition of Foresight Diagnostics for up to $450 million, consisting of $275 million upfront in stock and up to $175 million in revenue- and reimbursement-linked milestones. The deal brings Foresight’s ultrasensitive PhasED-Seq MRD and liquid-biopsy capabilities into Natera’s Signatera platform, strengthening Natera’s oncology and lymphoma diagnostics capabilities and accelerating clinical and biopharma partnerships.

LabGenomics USA LLC Acquires QDx Pathology

September 5, 2023

Healthcare Services

LabGenomics USA LLC, a subsidiary of South Korea–based LabGenomics Co., Ltd., has acquired QDx Pathology, a U.S. clinical and molecular pathology laboratory. The deal, signed in August 2023, is intended to accelerate LabGenomics' entry and expansion into the North American diagnostics market by combining QDx's lab services with LabGenomics' NGS-based molecular diagnostics capabilities.